Craniofacial and dental features in children aged 3-5 years with congenital Zika syndrome.

OBJECTIVE: Zika virus infection has been associated to congenital zika syndrome (CZS) in newborns and is characterized by microcephaly, central/axial motor and sensory dysfunction, dysphagia among other previously described severe health complications. CZS is usually diagnosed postpartum by evident/apparent neural development problems. Although there are some reports of craniofacial/dentition development in CZS, several clinical oral aspects are still unknown. This study describes some structural and functional characteristics of facial and cranial growth and deciduous dentition in CZS-affected children. MATERIAL AND METHODS: Some cranial, facial and dental characteristics were determined in 14 children with CZS aged 3-5 years and compared them against 12 apparently healthy children paired by age and gender. RESULTS: Fourteen CZS cases presented microcephaly, maxillary prognathism, altered facial thirds, asymmetric pupillary line, bruxism (p = 0.006), deep and anterior open bite and distal step decidual molar relationship (p = 0.031). CZS children cannot feed by themselves and most cannot walk and have not develop coordinated and intelligible language according to their chronological age. In contrast, controls presented normal skull features, have autonomous locomotion skills, speak intelligible language, feed by themselves, presented a harmonic intermaxillary relationship and have symmetrical facial thirds. CONCLUSION: Microcephaly, dysphagia, bruxism, mandibular retrognathia, altered facial proportions and malocclusion are the main craniofacial and oral features at CZS. CLINICAL RELEVANCE: The complications of CZS including those related with the face and the oral cavity are still being identified. This study revealed some cranial, facial and oral features in children affected by CSZ. Interdisciplinary rehabilitation protocols must address these syndromic features that could improve children and parents living conditions.

Los servicios de odontología en los tiempos del COVID- 19 en Colombia: análisis de país

Se desconoce el impacto que produjo la pandemia por el COVID-19 en la prestación y en la consulta de los servicios odontológicos y analizados según el sistema integrado de protección social o SISPRO en Colombia. El objetivo fue Determinar los cambios en la cobertura y los patrones de atención odontológica, entre los años pre pandemia (2017-2019) y los años de pandemia (2020-2021). Se analizaron los registros de las atenciones odontológicas reportadas en el sistema SISPRO del Ministerio de Salud de Colombia en periodos prepandemia y postpandemia por el COVID-19. En el año 2019 la tasa de cobertura por cada 100 habitantes en el estudio era de 31,14; sin embargo, la cobertura de atención odontológica se redujo al 17% en el 2020 y al 9% en el 2021 y las atenciones de urgencias disminuyeron drásticamente en los años 2020 y en el 2021. Se requiere que los tomadores de decisión promuevan los servicios de odontología para recuperar los niveles de cobertura previos a la pandemia. Se identificó una disminución en la cobertura odontológica asociada a la pandemia de la COVID-19 en los años 2020 y 2021 y desconocen cuales son los posibles efectos en la morbilidad bucal de los Colombianos.

Introduction. The COVID-19 pandemic affected Colombian dental services from March 2019 to now, but its magnitude is unknown. Objective. To determine dental care coverage in Colombia during the pandemic period and compare these data with the pre-pandemic period 2017-2019. Methods. Dental coverage and consultation services registered in the "Sistema Integrado de Protección Social" or SISPRO from 2017 to 2021 were analyzed. Results. The whole dental service coverage rate was nearly 20% before Covid-19 pandemic and even registered a slight increase from 2017 to 2018 at national and at department levels. This dental national coverage was 31,14% for every 100 habitants in 2019. However, there was a sharp reduction to 17% in 2020 and to 9% in 2021, revealing a clear and negative impact of the pandemic in dental coverage services and in dental emergency services. Conclusion. A decrease in dental coverage during to the COVID-19 pandemic is revealed, with a concomitant reduction in dental emergency consultations during 2020 and 2021 at country level. The consequences of this disruption on the oral and dental epidemiological profile of Colombians is still unknown and might require urgent preventive, promotional and curative care actions to recover the pre-pandemic dental coverage levels.

A Mouthwash with Cetylpyridinium Chlorideis reducing salivary SARS-CoV-2 viral load in +COVID-19 / Un enjuague con Cloruro de Cetilpiridinio redujo la carga salival del virus SARSCoV-2 en pacientes con Covid-19

Aim: The aim of this randomised, double-blind, placebo-controlled pilot clinical trial is to evaluate the capacity of a mouthwash to reduce SARS-CoV-2 viral load in the saliva of patients with COVID-19. Methods: Twenty-three symptomatic SARS-CoV-2-positive outpatients were selected andrandomised into two groups and registered at NTC 04563689. Both groups rinsed and gargled for one minute with either distilled water (Placebo) or with 0.05% Cetylpyridinium chloride (CPC) plus 0.12% Chlorhexidine (CHX) mouthwash (PERIOAID Intensive Care). Saliva samples were collected before the use of placebo or mouthwash and after 15 minutes and 1 and 2 hours of either of the above treatment. A saliva sample was also taken five days after regular use of placebo or mouthwash twice daily. The virus was detected by qRT-PCR. Results: A great heterogeneity in the viral load values was observed at baseline in both groups for nasopharyngeal and saliva samples. Most of the patients who used the mouthwash (8/12) had a significant decrease in baseline viral load after 15 min (greater than 99% reduction). This inhibitory effect was maintained for up to two hours in 10 of the 12 patients. At five days, SARS-CoV-2 RNA was detectedin only 1 patient from the mouthwash group and in 5 from the placebo group. Conclusions: This study points out that a CPC mouthwash can reduce the viral load in saliva of COVID-positive patients. This finding may be important in transmission control of SARS-CoV-2. Nevertheless, the clinical relevance of CPC mouthwash-reduction on SARS-CoV-2 shedding in saliva requires further study.

Objetivo: El objetivo de este ensayo clínico piloto aleatorizado, doble ciego y controlado con placebo es evaluar la capacidad de un enjuague bucal para reducir la carga viral del SARS-CoV-2 en la saliva de pacientes con COVID-19. Materiales y métodos:Veintitrés pacientes ambulatorios positivos para SARS-CoV-2 sintomáticos fueron seleccionados y aleatorizados en dos grupos y registrados en el NTC 04563689. Ambos grupos se enjuagaron y hicieron gárgaras durante un minuto con agua destilada (placebo) o con cloruro decetilpiridinio al 0 ,05 % (CPC). ) más enjuague bucal con Clorhexidina (CHX) al 0,12% (PERIOAID Intensive Care). Se recolectaron muestras de saliva antes del uso de placebo o enjuague bucal y después de 15 minutos y 1 y 2 horas de cualquiera de los tratamientos anteriores. También se tomó una muestra de saliva cinco días después del uso regular de placebo o enjuague bucal dos veces al día. El virus fue detectado por qRT-PCR. Resultados:Se demostró una gran heterogeneidad en los valores de carga viral al inicio del estudio en grupos ambos para muestras de nasofaringe y saliva. La mayoría de los pacientes que usaron el enjuague bucal (8/12) tuvieron una disminución significativa en la carga viral inicial después de 15 minutos (reducción superior al 99 %). Este efecto inhibidor se mantuvo hasta dos horas en 10 de los 12 pacientes. A los cinco días, se detectó ARN del SARS-CoV-2 en solo 1 paciente del grupo de enjuague bucal y en 5 del grupo de placebo. Conclusiones:Este señala que un enjuague bucal CPC puedereducir la carga viral en saliva de pacientes COVID positivos. Este hallazgo puede ser importante en el control de la transmisión del SARS-CoV-2. Sin embargo, la relevancia clínica de la reducción del enjuague bucal con CPC en la excreción de SARS-CoV-2 en la saliva requiere más estudios.

La promoción de la salud general y la salud oral: una estrategia conjunta / Health prevention and promotion strategies and their relationship with gingival and periodontal health

Cerca de 600 millones de latinoamericanos viven en los 22 países y territorios que comprenden desde México y el Caribe hasta la Argentina y Chile en el Sur, en donde los desarrollos económicos y sociales son muy variados, pero en donde, además, la caries dental y las periodontitis afectan a elevados porcentajes de la población. Este artículo describe una estrategia poblacional para combinar la adopción de estilos de vida saludable para el control de las enfermedades crónicas no transmisibles y de las enfermedades orales, usando como pilares en la estrategia la promoción, la prevención y la educación a nivel individual y poblacional de los individuos sanos. Esta estrategia se contrapone con los actuales modelos curativos que demandan alta inversión y recursos físicos-humanos para el tratamiento de la enfermedad crónica y de las enfermedades orales.

Latin America is populated by approximately 600 million inhibitants living in 20 countries, from Mexico and the Caribean in the north to Argentina and Chile in the south, and although they have a varied social and economic development, oral diseases are common and affect a significant percentage of the population. This article describes a public health strategy to control both chronic, non-communicable disease and periodontal and oral disease, based on health promotion and disease prevention outside of dental clinics.

La moxifloxacina como coadyuvante en el tratamiento de las periodontitis / Moxifloxacine an adjunct in the treatment of periodontitis

La enfermedad periodontal es causada por complejos bacterianos subgingivales organizados en una biopelícula, que genera beneficios ecológicos y metabólicos a los microorganismos que residen en ella. Por otro lado, la biopelícula también genera ventajas contra los mecanismos de defensa del huésped representados en antimicrobianos naturales o contra los antibióticos sintéticos. Pacientes de Centroamérica y Sudamérica tienen perfiles microbiológicos similares en periodontitis agresivas como crónicas. En ambas entidades, los periodontopatógenos más frecuentes asociados con la enfermedad periodontal en los pacientes latinoamericanos son Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, Prevotella intermedia, Prevotella nigrescens, Tannerella forsythia, Eikenella corrodens y bacilos entéricos gramnegativos. Los antibióticos han sido prescritos como apoyo a la terapia mecánica para reducir la carga bacteriana a nivel subgingival. Sin embargo, algunas especies bacterianas han desarrollado resistencia antimicrobiana debido a la prescripción indiscriminada de antibióticos, en especial en Latinoamérica. Las quinolonas representan una nueva alternativa en la terapia periodontal debido a su actividad contra los periodontopatógenos y los bacilos entéricos gramnegativos puesto que tienen una reducida resistencia bacteriana, y tienen alta difusión tisular y buena absorción. Se realizó una revisión de literatura con el propósito de brindar una actualización en el uso de antimicrobianos como terapia coayudante en el tratamiento de la periodontitis, enfocando el potencial terapéutico de la moxifloxacina como nueva alternativa.

Periodontal disease results from infection by specific subgingival bacterial complexes organized in a biofilm. Biofilm protects bacteria and other microbial pathogens from host immune system defenses and from natural and artificial antibiotics. Patients with aggressive and chronic periodontitis from Central and South American countries have similar microbiological profiles. In both entities, the most frequent periodontopathogens associated with periodontal disease in Latin American patients are Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, Prevotella intermedia, Prevotella nigrescens, Tannerella forsythia, Eikenella corrodens and gram negative enteric rods. Supplemental antibiotics to the mechanical periodontal treatment are prescribed to reduce periodontopathic bacteria in the subgingival environment. Nonetheless, some bacterial species have developed antibiotic resistance due to their indiscriminate prescription in Latin America. Quinolones represent a new alternative in periodontal therapy, due to their activity against periodontopathogens and gram negative enteric rods, to reduced bacterial resistance, high tissue penetration, and good absorption. The aim of this review is to present an update on the use of antimicrobials as adjunctive therapy in the treatment of periodontitis, focusing on the potential therapeutic use of moxifloxacin.

Cultivo y Caracterización In Vitro de una Línea Celular de Fibroblastos Gingivales Humanos / In vitro culture and characterization of a cell line of human gingival fibroblasts

The main goal is to establish a cellular line of fibroblast which come from human gingival tissue, identifying its morphologic featores. Samples were taken from gum of healthy patients without medical antecedents. Three females and three male were selected. Ages were between 16 and 30 years old. A sample of 0,5 cm² of gum was obtained to take it to a cellular growth environment. Cultures were incobated at 37C, CO² atmosphere at 5% for ten (10) days. Samples were observed daily with inverted light Microscope Olimpus II. At 6th day growth of fusiform cells was observed; their morphology was in coincidence with that of the fibroblasts, At 18th day a monolayer of 100% purity was observed. The cellular line was preserved and stored by freezing in liquid nitrogen.